Dovzhanskiy Dmitriy I, Bischoff Moritz S, Passek Karola, Böhner Hinrich, Böckler Dittmar
Department of Vascular and Endovascular Surgery University Hospital Heidelberg Heidelberg Germany.
St. Rochus Hospital Castrop-Rauxel, Katholisches Krankenhaus Dortmund-West Castrop-Rauxel Germany.
Health Sci Rep. 2025 Apr 18;8(4):e70732. doi: 10.1002/hsr2.70732. eCollection 2025 Apr.
The variety of modern antithrombotic medications complicates the choice of individual perioperative therapy in vascular surgery, especially when more than one antithrombotic option is possible. The aim of this study was to determine the perioperative and periinterventional setting concerning antithrombotics in vascular surgery in Germany.
This article is based on a survey from year 2018 of heads of German vascular surgical departments or units regarding their experience with different anticoagulants. The survey asked for the frequency and time of preoperative pausing of the antithrombotics before various vascular operations or interventions.
The evaluable response rate was 52% (169/324). Acetylsalicylic acid was discontinued before open aortic surgery in 9% (15/169) of respondents. Clopidogrel was paused in 65% (107/169) before open aortic surgery, in 25% (41/169) before vascular surgery (like carotid endarterectomy, endovascular aortic repair, or operations on peripheral arteries), and in 11% (18/169) before peripheral percutaneous interventions. Discontinuation of vitamin K antagonists or direct oral anticoagulants (took place before conventional operations in 99.4%; oral anticoagulation was continued for peripheral percutaneous interventions in only 6% (8/169). Management was heterogeneous with regard to the timing of the perioperative medication pause. Clopidogrel was not discontinued according to time specifications in 8%; ticagrelor in 75%; rivaroxaban in 23%; and dabigatran in 29%, compared to the recommendations of the industrial information sheets.
The perioperative antithrombotic therapy in German vascular surgery clinics is not uniform and does not correspond to the current specialist recommendations in a notable proportion of clinics.
现代抗血栓药物种类繁多,这使得血管外科手术中个体化围手术期治疗的选择变得复杂,尤其是当存在多种抗血栓选择时。本研究的目的是确定德国血管外科手术中抗血栓药物的围手术期和围介入期情况。
本文基于2018年对德国血管外科科室或单位负责人进行的一项关于他们使用不同抗凝剂经验的调查。该调查询问了在各种血管手术或介入操作前停用抗血栓药物的频率和时间。
可评估的回复率为52%(169/324)。在开放性主动脉手术前,9%(15/169)的受访者停用了乙酰水杨酸。在开放性主动脉手术前,65%(107/169)的受访者停用了氯吡格雷;在血管手术(如颈动脉内膜切除术、血管腔内主动脉修复术或外周动脉手术)前,25%(41/169)的受访者停用了氯吡格雷;在外周经皮介入操作前,11%(18/169)的受访者停用了氯吡格雷。维生素K拮抗剂或直接口服抗凝剂在99.4%的常规手术前停用;在外周经皮介入操作中,仅6%(8/169)的受访者继续口服抗凝治疗。围手术期药物停用时间的管理存在异质性。与行业说明书的建议相比,8%的受访者未按时间规范停用氯吡格雷;75%的受访者未按时间规范停用替格瑞洛;23%的受访者未按时间规范停用利伐沙班;29%的受访者未按时间规范停用达比加群。
德国血管外科诊所的围手术期抗血栓治疗并不统一,在相当一部分诊所中与当前的专家建议不符。